IMerge Phase 3: Long-Term Results of Imetelstat in Lower-Risk MDS | Valeria Santini, MD

IMerge Phase 3: Long-Term Results of Imetelstat in Lower-Risk MDS | Valeria Santini, MD

Optimal 2nd-Line Treatment for CLL? GAIA/CLL13 Findings | Carsten Niemann, MD

Optimal 2nd-Line Treatment for CLL? GAIA/CLL13 Findings | Carsten Niemann, MD

Treating High Risk Smoldering Multiple Myeloma- Aquila Updates | Natalie Callander, MD

Treating High Risk Smoldering Multiple Myeloma- Aquila Updates | Natalie Callander, MD

Your Voice Matters: The Power of Patient-Reported Outcomes in Myeloma | Fabio Efficace, PhD

Your Voice Matters: The Power of Patient-Reported Outcomes in Myeloma | Fabio Efficace, PhD

Updates -Smoldering Multiple Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP

Updates -Smoldering Multiple #Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP

Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD

Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD

S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD

S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD

Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc

Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc

Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD

Making CAR-T Cells inside the body? inMMyCAR Trial Insights | Natalie Callander, MD

Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD

Does MGIP represent the earliest stage of myeloma? | Sungjae Kim, PhD

Etentamig in patients with relapsed refractory amyloidosis | Rajshekhar Chakraborty, MD